Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-World Effectiveness of DAA Therapies in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection: 996 Veterans Can't Be Wrong.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 15 Jun 2017

Burton Mary Jane, Naggie Susanna

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Coinfection
Share to Genotype
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to HIV Infections

Share to Veterans

Source

Identifiers

PMID: 28199517
DOI: 10.1093/cid/cix117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Effectiveness of DAA Therapies in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection: 996 Veterans Can't Be Wrong.PMID 28199517Read ↗

Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infections.Semantic proximity Read ↗

Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.Semantic proximity Read ↗

Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting.Semantic proximity Read ↗

Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.Semantic proximity Read ↗

No compelling reason to adopt new antivirals whenever it is reasonable to wait.Semantic proximity Read ↗

Advances in the pharmaceutical care of hepatitis C/HIV co-infection.Semantic proximity Read ↗

Direct-acting Antivirals for HIV/HCV Co-infected Individuals: As Good as it Gets?Semantic proximity Read ↗

Management of direct-acting antiviral agent failuresSemantic proximity Read ↗

Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009Semantic proximity Read ↗

Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.Semantic proximity Read ↗

Prevalence of drug-drug interactions with pangenotypic direct-acting antivirals for hepatitis C and real-world care management in the United States: a retrospective observational study.Semantic proximity Read ↗

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.